Mediwound reports first quarter 2023 financial results and provides a company update

On track to initiate escharex ® phase iii study in fourth quarter 2023 nexobrid ® u.s. launch expected in early third quarter 2023 cash of over $57 million; operating cash runway through profitability
MDWD Ratings Summary
MDWD Quant Ranking